Phaseline

Companies › Xcovery Holdings

Xcovery Holdings: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Ensartinib (X-396)
ALK tyrosine kinase receptor inhibitor
ALKPhase 3Non-small Cell Lung Cancer–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT02767804Ensartinib (X-396)Phase 3Non-small Cell Lung CancerOncologyDec 2025

Targets

ALK (1)

Companies with the same targets

Pfizer Roche IDEAYA Biosciences CStone Pharmaceuticals Ascentage Pharma Group Novartis Shenzhen TargetRx Nuvalent Shanghai Fosun Pharmaceutical Industrial Development TRIANA Biomedicines

Companies built like this

Shenzhen TargetRx Verity Pharmaceuticals SecuraBio Fidia Farmaceutici Sumitomo Pharma Switzerland

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.